Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations.

PURPOSE There is an increasing need to identify molecular markers, which can be used to prognosticate patient populations in gastric cancer. Whereas a significant number have been identified, very few have been characterized in the context of their ability to discriminate between young and old age groups in which a survival difference clearly exists. MATERIAL/METHODS In this study, using immunohistochemistry, we evaluated three markers with proven involvement in gastric cancer. The p53 tumor suppressor, the cell adhesion glycoprotein epithelial cadherin (CDH1) and the caudal-related homeobox transcription factor (CDX2) all of these have important roles in the aetiopathogenesis and/or progression of gastric cancer. RESULTS After adjustments for TNM stage, tumor grade, histopathological characteristics (Lauren classification), we found significant differences in the expression of these proteins, particularly E-cadherin and CDX2 between young and elderly patients. However, these differences did not amount to a significant difference in survival. CONCLUSIONS This study demonstrates that the protein expression of p53, CDH1 and CDX2 significantly discriminates young patients with gastric cancer who have a better prognostic outlook from older patients, but this difference in expression does not contribute to a survival benefit.

[1]  H. Kuwano,et al.  Prognostic significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer. , 2006, European Journal of Cancer.

[2]  Young-Kyu Park,et al.  Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. , 2005, World journal of gastroenterology.

[3]  J. Ge,et al.  A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[5]  Y. Kodera,et al.  Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry , 2012, Gastric Cancer.

[6]  S. Cai,et al.  Abnormal expression of E‐cadherin in tumor cells is associated with poor prognosis of gastric carcinoma , 2012, Journal of surgical oncology.

[7]  K. Dameron,et al.  The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. , 1994, Cold Spring Harbor symposia on quantitative biology.

[8]  Y. Bang,et al.  Metastasis-Associated Protein S100A4 and p53 Predict Relapse in Curatively Resected Stage III and IV (M0) Gastric Cancer , 2008, Cancer investigation.

[9]  J. Roh,et al.  Gastric cancer in young patients who underwent curative resection. Comparative study with older patients. , 1996, American journal of clinical oncology.

[10]  Yongfei Wang,et al.  The prognostic value of E‐cadherin in gastric cancer: A meta‐analysis , 2013, International journal of cancer.

[11]  T. Saito,et al.  Early gastric cancer in the young: clinicopathological study. , 1999, The Australian and New Zealand journal of surgery.

[12]  K. Höffken,et al.  Gastric cancer in very young adults: apropos four patients and a review of the literature , 2000, Journal of Cancer Research and Clinical Oncology.

[13]  R. Qin,et al.  Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions. , 2012, World journal of gastroenterology.

[14]  Yongning Zhou,et al.  Expression of E-cadherin and beta-catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. , 2002, World journal of gastroenterology.

[15]  D. Shen,et al.  PTEN expression and suppression of proliferation are associated with Cdx2 overexpression in gastric cancer cells. , 2013, International journal of oncology.

[16]  W. Kim,et al.  Molecular Pathology of Gastric Carcinoma , 2011, Pathobiology.

[17]  T. Yagi,et al.  Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. , 2000, Genes & development.

[18]  M. Brennan,et al.  Gastric Cancer in Young Patients: Demographic, Clinicopathological, and Prognostic Factors in 92 Patients , 2000, Annals of Surgical Oncology.

[19]  K. Kumamoto,et al.  CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. , 2009, Oncology reports.

[20]  E. Busse Advances in medical science. , 1968, The Gerontologist.

[21]  D. Stippel,et al.  p53 Expression in Gastric Cancer (Clinicopathological Correlation and Prognostic Significance) , 1997, Digestive Diseases and Sciences.

[22]  A. R. Gonçalves,et al.  Prognostic Significance of p53 Protein Expression in Early Gastric Cancer , 2011, Pathology & Oncology Research.

[23]  S. Hirohashi,et al.  p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. , 1991, Cancer research.

[24]  Yubo Xie,et al.  Overexpression of Cdx2 inhibits progression of gastric cancer in vitro. , 2009, International journal of oncology.

[25]  M. Magnani,et al.  Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer , 2004, Clinical Cancer Research.

[26]  Q. Xiao,et al.  Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures , 2012, Journal of experimental & clinical cancer research : CR.

[27]  D. Park,et al.  CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance , 2010, Modern Pathology.

[28]  S. Groshen,et al.  Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. , 2011, Journal of gastrointestinal oncology.

[29]  F. Lordick,et al.  Prognostic and Putative Predictive Biomarkers of Gastric Cancer for Personalized Medicine , 2013, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[30]  P. K. Wright,et al.  Downregulation of CDX2 in gastrointestinal neoplasia , 2013, Journal of Clinical Pathology.

[31]  I. Sporea,et al.  The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients. , 2010, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[32]  F. Schildberg,et al.  Differences in the treatment of young gastric cancer patients: patients under 50 years have better 5-year survival than older patients. , 2012, Advances in medical sciences.

[33]  Y. Kodera,et al.  Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry , 2011, Gastric Cancer.

[34]  A. Egashira,et al.  Overexpression of Hypoxia-Inducible Factor 1α and p53 Is a Marker for an Unfavorable Prognosis in Gastric Cancer , 2006, Clinical Cancer Research.

[35]  Hermann Brenner,et al.  Epidemiology of stomach cancer. , 2009, Methods in molecular biology.

[36]  Y. Ru,et al.  Detection and Clinical Significance of Lymph Node Micrometastasis in Gastric Cardia Adenocarcinoma , 2012, The Journal of international medical research.

[37]  E. Dolar,et al.  Expression of p53 Protein and Prognosis in Gastric Carcinoma , 1999, The Journal of international medical research.

[38]  Y. Kakeji,et al.  Age‐related characteristics of gastric carcinoma in young and elderly patients , 1996, Cancer.